REGN Furnishes earnings results
Summary
Regeneron Pharmaceuticals, Inc. expects to include an acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis in its third quarter 2025 GAAP and non-GAAP financial results. This charge primarily relates to a previously disclosed $80 million up-front payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The acquired IPR&D charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share for the third quarter 2025 by approximately $0.68. * Charge amount: ~$83 million pre-tax. * EPS impact: ~$0.68 negative per diluted share. * Related to: $80 million up-front payment to Hansoh Pharmaceuticals. * Agreement: 2025 license agreement.
Why It Matters
Investors should note the expected $83 million IPR&D charge, which is projected to negatively impact Q3 2025 GAAP and non-GAAP net income per diluted share by approximately $0.68, as this represents a material preliminary financial adjustment.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Key Quote
“the 2025 license agreement. The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Monday, October 6, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- medium
- Sentiment
- positive